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Introduction: Hypokalaemia is a common clinical problem. A potential but commonly over-
looked cause of hypokalaemia is Gitelman syndrome.
Material and methods: A 26-year-old man was admitted to the hospital due to syncope with
general and muscular weakness and muscle cramps. The patient’s history revealed previ-
ous  recurrent syncope events associated to hypokalaemia with the lowest serum potassium
value  being 2.6 mmol/l. At admission, blood pressure was normal and no changes were found
at  physical examination. Laboratory tests showed mild hypokalaemia (3.0 mmol/l), hypo-
magnesaemia (1.36 mg/dl), hypocalciuria (< 40 mg/24 h), and metabolic alkalosis (HCO3−
29.7 mmol/l, BE 5.3 mmol/l).
Results: Further laboratory tests (FeK, TTKG) conﬁrmed inappropriate kaliuresis. Conn’s dis-
ease was excluded by hormonal and imaging assessments. Genetic testing was performed
and two novel heterozygous mutations: c.35 36insA and c.1095+5G>A were found in tran-
script NM 000339.2 in SLC12A3 gene.
Conclusion: The patient was diagnosed with Gitelman syndrome and was  treated with sup-
plements of potassium and magnesium.
© 2015 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/
by-nc-nd/4.0/)
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El  caso  del  síndrome  de  Gitelman  causado  por  dos  nuevas  mutaciones  en
el  gen  SLC12A3
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Introducción: La hipopotasemia es un problema clínico común. El síndrome de Gitelman es
una posible causa de hipopotasemia a veces no reconocida.
Material y métodos: Un hombre de 26 an˜os de edad ingresa en un hospital por causa de un
síncope, debilidad generalizada y calambres musculares. La historia clínica del paciente
reveló la incidencia del síncope con hipopotasemia recurrente con el valor más  bajo de
potasio en 2,6 mmol/l. En el ingreso, el paciente presentaba una presión arterial normal y la
exploración física no reveló ninguna enfermedad. La evaluación del laboratorio demostró
una  hipopotasemia leve (K+ 3,0 mmol/l), hipomagnesemia (Mg  1,36 mg/dl), hipocalciuria
(<40 mg/24 h) y alcalosis metabólica (HCO3- 29,7 mmol/l, exceso de base 5,3 mmol/l).
Resultados: Otras pruebas de laboratorio (FeK, TTKG) conﬁrman una caliuresis inadecuada. La
enfermedad de Conn fue excluida tras la evaluación hormonal y radiológica. Se realizaron
las  pruebas genéticas y 2 mutaciones heterocigóticas: c.35 36insA y c.1095+5G>A fueron
encontradas en la transcripción NM 000339.2 del gen SLC12A3.
Conclusión: El paciente fue diagnosticado con el síndrome de Gitelman y fue tratado con
suplementos de potasio y magnesio.
© 2015 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo  Open Access bajo la CC BY-NC-ND licencia. (http://creativecommons.org/licencias/
by-nc-nd/4.0/)
Introduction
Hypokalemia is a common clinical problem in endocrinol-
ogists’ and nephrologists’ practice. There are many  obvious
causes of hypokalemia such as diarrhea, vomiting or diuretics
abuse. Other causes such as tubulopathies are rarely observed
and their diagnosis is more  challenging. There are many
inherited and acquired tubulopathies causing hypokalemia,
sometimes severe and life-threatening.1
A relatively common but overlooked cause of hypokalemia
is Gitelman syndrome (GS).2 It is a recessive salt-losing tubu-
lopathy caused by the SLC12A3 gene mutation. SLC12A3 gene
encodes the thiazide-sensitive transporter NCCT (sodium
chloride co-transporter). NCCT is located in the distal convo-
luted tubular cells (DCC), which are responsible for 7–10% of
electrolyte tubular absorption.3
The most severe laboratory abnormalities found in GS are
hypokalemia and hypomagnesaemia caused by renal K+ and
Mg2+ wasting. Other typical changes are metabolic alkalo-
sis, hypocalciuria and hyperreninemic hyperaldosteronism.4
Mild to moderate hypophosphatemia is frequently observed.5
Severe hypophosphatemia with severe hyponatremia was also
reported.6,7
First symptoms of GS occur in children or young adults with
normal growth and history of salt-craving behaviors (children
eager to consume pickle or brine, salted cucumbers, oranges
and lemons, children licking salt from potato crisps, etc.).8
Clinical presentation varies among patients. Some are asymp-
tomatic but others develop life-threatening complications.
Males manifest a more  severe phenotype than females.8 The
most common symptoms are muscular cramps and weakness,
constipation, nocturia, polyuria, thirst, polydipsia, cardiac
arrhythmias, paresthesias and increased salt appetite. Arterial
hypotension is common and in many  cases the most promi-
nent symptom, however, in aging GS population hypertension
can occur.8 The correlation between biochemical abnormal-
ities and symptoms is not strong.9 GS does not interfere
with children’s moods and social relationships.9,10 Otherwise
symptoms are more  common in adults and can have negative
impact on their quality of life. Forty-ﬁve percent of GS patients
consider their symptoms as a moderate to big problem.11
Extreme exhaustion, muscular weakness, paresthesias, severe
fatigue and hypotension are associated with mild to severe
reduction in daily activities.9
Estimated prevalence of GS is 1:40,0008 and the prevalence
of heterozygous is at least 1% in the European population.
More  than 180 different mutations in SLC12A3 have been
described until now.12
Case  report
A 26-year-old male was admitted to the hospital due
to incidence of syncope, generalized and muscular weak-
ness and muscle cramps. The patient’s history revealed an
episode of syncope with potassium level 3.16 mmol/l. In
further follow up in outpatient assessment, recurrent inci-
dence of hypokalemia (the lowest value 2.6 mmol/l) was
observed. Blood pressure was normal 110/80, heart rate was
72 per minute; there was no changes in physical examina-
tion. Nor neurological ﬁndings, weight 74 kg, height 178 cm.
On admission to hospital laboratory evaluation showed
mild hypokalemia (K+ 3.0 mmol/l), hypomagnesaemia (Mg2+
1.36 mg/dl), hypocalciuria (<40 mg/24 h), and metabolic alka-
losis (HCO3− 29.7 mmol/l, BE 5.3 mmol/l). Kidney function was
good with eGFR > 60 ml/min. Imaging studies were unremark-
able, so was the ECG.
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Table 1 – The values diagnostic for hypokalemia.13–15
Values diagnostic
for inappropriate
kaliuresis
Patient
Urinary K+
[mmol/24 h]
>20 mmol/24 h
If serum
K+ < 3.5 mmol/l
57  mmol/l
(serum
K+ = 3.0 mmol/l)
FeK = [(urine
K+ × serum
creatinine)/(serum
K+ × urine
creatinine)] × 100%
>6.5%
If serum
K+ < 3.5 mmol/l
12%
(serum
K+ = 3.0 mmol/l)
TTKG = [urine
K+ × serum
osmolality] [serum
K+ × urine
osmolality]
TTKG > 2
If serum
K+ < 3.5 mmol/l
7.3
(serum
K+ = 3.0 mmol/l)
uK/Cr – random
urine K+ to
creatinine ratio
uK/Cr > 15 mmol/g
If serum
K+ < 3.5 mmol/l
67  mmol/g
(serum
K+ = 3.0 mmol/l)
Further investigations conﬁrmed that hypokalemia was
caused by renal potassium wasting. The 24-h potassium wast-
ing, transtubular K+ gradient (TTKG), fractional K+ excretion
(FeK) and random K/creatinine ratio (K/Cr) were typical for
hyperkaliuria and are shown in Table 1.13–15 Daily magnesiuria
was 64 mg/24 h, with fractional magnesium (FeMg) excretion
15%.
Although blood pressure was normal, hormonal tests to
exclude Conn’s disease and the abdominal CT were per-
formed, and did not reveal any abnormalities in adrenal
glands. Secondary hyperaldosteronism with levels of aldos-
terone 289 pg/ml (normal range 20–180) and renin 205 mIU/ml
(normal range 2.8–39.9) were typical for GS.
The patient was diagnosed as GS on the basis of a clinical
phenotype. After the diagnosis, treatment with supplements
of potassium and magnesium was introduced. He received
20 mmol  of potassium chloride and 18 mmol  of magnesium
pyrrolidone carboxylate, with clinical improvement. Fam-
ily history revealed mild asymptomatic hypokalemia in the
patient’s 35-year-old sister. But investigations showed neither
hyperkaliuria nor hypomagnesaemia. GS was not diagnosed
in this case.
Genetic  analysis
According to the genetic analysis, algorithm proposed by
Nozu16 SLC12A3 gene should be tested in patients with
hypokalemic metabolic alkalosis, with full term birth, nor-
mal  weight without nephrocalcinosis, with hypocalcuria and
hypomagnesaemia.
In the described case genetic testing was performed and
two heterozygous mutations: c.35 36insA and c.1095+5G>A
were found in transcript NM 000339.2 of the SLC12A3 gene
(Fig. 1). Both mutations are not yet in the HGMD(r) database
version available [HGMD® Professional 2013.2 – 28th June
2013]. The ﬁrst mutation was also found in patient’s mother
and the second in father. Only one of the two mutations iden-
tiﬁed in our patient c.35 36insA was found in his sister.
The mutations found in this patient almost prove the
clinical diagnosis of GS. The pathogenetic relevance of the
frameshift mutation is obvious. We  cannot be sure about the
pathogenetic relevance of the splice site mutation of intron 8.
The consensus splice sequence G (100%), T (100%), A (62%), A
(68%), G (82%), T (63%) at the splice donor of intron 8 does not
exactly match the consensus GTgAGc. The mutation found in
this patient further deviates the sequence from the consensus
(GtgAac). Also, in silico analysis by mutation taster considers
this mutation as disease causing.17
Discussion
Tubulopathies are rare diseases. According to RenalTube
database18 the most common primary tubulopathies in Euro-
pean population are distal renal tubular acidosis, Bartter
syndrome, familial hypomagnesaemia with hypercalciuria
and GS.18 The prevalence of GS is around 25 cases per 1
million.3 Because GS is one of the most common, probably
many nephrologists and endocrinologist will be confronted
with cases of GS during their careers. Our patient had typical
clinical presentation of GS and responded well to therapy. The
problem with GS is that overlooked hypokalemia could cause
death due to cardiac arrest or respiratory muscles paralysis.
The severe neuromuscular symptom such as hypokalemic
paralysis occurs in up to 6% of patients (more common in
Asian patients).3
The inherited tubulopathies have a kind of “mirror
images”-acquired tubulopathies caused by diuretics. Every
diuretic (to be precise: natriuretics, acquaretics or glu-
curetics) cause abnormalities similar to those found in
inherited tubulopathies (Table 2). Almost in every tubulopa-
thy polyuria occurs, and potassium level changes are among
the commonest problems. In patients with GS the muta-
tions of SLC12A3 gene are found. This gene is encoding
the thiazide-sensitive transporter. Therefore GS resembles
chronic treatment with thiazides.
Approach  to  hypokalemia
GS is also known as familial hypokalemic hypomagnesaemia,
because hypokalemia is the most common phenomenon. In
a patient with hypokalemia and suspicion of tubulopathy one
should conﬁrm hyperkaliuria. Renal potassium wasting can
be proved by calculating TKKG, FeK, random K/Cr ratio or after
24-h urine collection (Table 1). Assessment of kaliuria should
be performed, when the patient is taking neither diuretics nor
potassium supplementation and when the potassium level is
low. When potassium excretion is below 30 mmol/l and TTKG
is low, hypokalemia is caused by extrarenal loss or a transcel-
lular K+ shift.
When excessive potassium renal loss in patient with
hypokalemia is conﬁrmed, further diagnosis is based on pH
and blood pressure. In many  cases these simple studies will be
enough for diagnosis. An important problem of an increasing
interest is primary aldosteronism (PA). Some clinical studies
have suggested that PA is the cause of over 10% of arterial
hypertension (AH), and is more  common in patients with AH
resistant to antihypertensive agents.19 Hypokalemia is one of
n e f r o l o g i a 2 0 1 6;3  6(3):304–309 307
45
510
Nr Transcript Exon/Intro
515 520
Codo
nn
1 1 12 p.D12EfsX17 c.35_36insA
c.1095+5G>AIVS8+5G>A36582
n/a
n/a
heterozygous
heterozygous
NM_000339.2
NM_000339.2
Protein PMIDDNA Zygosity
Nr Transcript Exon/Intron Codon Protein PMIDDNA Zygosity
525 530 535 540 545
50 55 60 65 70 75 80
56
1095+211095+151095+91095+3109210861080
50443832262014
14 26 38 50
7572756075487536
Fig. 1 – Chromatograms of affected patient’s DNA sequencing.
the “classical” symptoms of PA, but is not so common as was
considered.20 Yet, because there is no gold standard in the
diagnosis of AP, it is worth remembering about RAA axis in
patients with AH and hypokalemia.19
Diagnosis  of  hypomagnesaemia
Hypomagnesaemia is a common abnormality in GS patients,
although it is not observed in every case.21 In normomagne-
semic patients with GS, clinical manifestation and electrolyte
abnormalities are milder.22
Similar to potassium ions, magnesium ones are freely
ﬁltered by the glomeruli. 10% of ﬁltered Mg2+ is absorbed
by the proximal tubule, 50–70% in ascending limb of
Henle’s loop. Distal reabsorption depends on epithelial Mg2+
TRPM6 channels. Magnesiuria depends on oral intake and
FeMg should be calculated to establish renal Mg2+ wast-
ing (FeMg = (urine magnesium × serum creatinine)/[0.7(serum
magnesium × urine creatinine)] × 100). FeMg less than 2% sug-
gests poor intake, GI losses or shift of Mg  into cells. FeMg
above 4% suggests renal Mg2+ wasting. When renal Mg  wast-
ing is proved, random Ca/Cr ratio should be calculated.
Urine Ca/Cr ratio <0.3 is typical in GS, isolated dominant
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Table 2 – Diuretics and tubulopathies.
Inherited single gene defect Potassium
concentration
Symptoms
similar to use
of:
Gene Gene product Gene product
location
Guibaud-Vainsel syndrome (RTA 3) ↓ Acetazolamide CA2 CA II Proximal
tubule
Renal glycosuria – SGLT2
inhibitorsa
(Canagliﬂozin,
Tofogliﬂozin,
Dapagliﬂozin)
SLC5A2 Sodium/glucose
cotransporter
2 (SGLT2)
Proximal
tubule
Bartter syndrome ↓ Furosemide SLC12A1b Na-K-2Cl
cotransporter
(NKCC2)
Loop  of Henle
Gitelman syndrome ↓ Thiazide SLC12A3 Thiazide-
sensitive
Na-Cl
cotransporter
Distal tubule
Diabetes insipidus – Vaptan AVPR2, AQP2 V2 receptor Collecting
duct
Pseudohypoaldosteronizm, AD ←↑ Spironolactone NR3C2 Spironolactone-
sensitive
mineralocor-
ticoid
receptor
Collecting
duct
Pseudohypoaldosteronizm, AR ↑ Amiloride SCNN1A,
SCNN1B,
SCNN1G
Amiloride-
sensitive
epithelial
sodium
channel
Collecting
duct
AR – autosomal recessive; AD – autosomal dominant.
a SGLT2 inhibitors (glucuretics) are the new drugs for the management of type 2 diabetes; during treatment osmotic diuresis-related events
such as pollakiuria and polyuria are observed.
b Although there are different Bartter genes this is the one that mimics furosemid.
hypomagnesaemia with hypocalciuria and in thiazide treat-
ment. Urine Ca/Cr ratio >0.3 is typical in hypermagesuria
in Bartter syndrome, so are isolated recessive hypomagne-
saemia with normocalciuria, familial hypomagnesaemia with
hypercalciuria and nephrocalcinosis, autosomal dominant
hypocalcemia with hypercalciuria, loop diuretics treatment
and nephropathy caused by some nephrotoxins.23
Magnesium and potassium homeostasis are related to each
other, and potassium depletion cannot be corrected until the
correction of hypomagnesaemia.23 On average patients should
receive up to 500 mEq  of potassium, 4–5 mg/kg/day of 5–10 mg
of magnesium chloride. Amiloride (5–10 mg/day) and spirono-
lacton (200–300 mg)  are helpful.3
Clinical symptoms and laboratory results are essential for
diagnosis. In cases with typical phenotype some authors rec-
ommend performing a thiazide test to conﬁrm diagnosis.24 In
presented case genetic investigation revealed two novel muta-
tions of SLC12A3 gene. They are probably caused by lack of
functional mutations of NCCT.
Conclusions
GS syndrome is one of the rare causes of hypokalemia, and
it seems a challenge for physicians. We  show in this paper
that if one remembers about a very simple approach to
hypokalemia and is aware of diuretics action and their sim-
ilarity to inherited tubulopathies, the diagnosis could be quite
straightforward. GS should be differentiated from other tubu-
lopathies (inherited as well as acquired), and other causes of
hypokalemia (e.g. Conn’s disease). Familial history can reveal
asymptomatic patients with GS. Suitable treatment protects
patients from potentially dangerous complications.
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